Calcitonin Gene-Related Peptide Antibody for Prevention of Acute Mountain Sickness: A Prospective Single-center, Randomized, Placebo-controlled, Double-blinded Study

Acute mountain sickness (AMS) is a common condition that can occur when healthy people travel quickly to high altitude. Typical symptoms include headache, nausea, tiredness, dizziness, and poor sleep. In most cases, AMS improves with rest and by not climbing higher, but it can make mountaineering difficult and, in severe cases, can lead to dangerous complications.
The biological mechanisms that cause high-altitude headache and AMS are not yet fully understood. Some symptoms of AMS are similar to migraine, suggesting that both conditions may share common pathways in the nervous system. One possible pathway involves calcitonin gene-related peptide (CGRP), a substance known to play an important role in migraine.
Fremanezumab is an approved monoclonal antibody used to prevent migraine. It works by binding to CGRP and reducing its biological activity. This study will investigate whether a single dose of fremanezumab can also help prevent symptoms of AMS and high-altitude headache in healthy adults exposed to high altitude. To date, there are no clinical data on the effect of fremanezumab in AMS or high-altitude headache.
This is a prospective, randomized, double-blind, placebo-controlled, parallel-group clinical trial. A total of 30 healthy adult volunteers will participate. Participants will be randomly assigned in a 1:1 ratio to receive either a single subcutaneous injection of fremanezumab 225 mg or placebo (saline). Neither the participants nor the investigators will know which treatment was given during the study. The study medication will be administered 1 week before ascent to Capanna Regina Margherita at 4554 meters above sea level. Participants will remain there for 46 hours under hypobaric hypoxic conditions.
The main goal is to determine whether fremanezumab reduces the severity of AMS compared with placebo. AMS symptoms will be measured using the Lake Louise Score, a standard questionnaire commonly used in altitude medicine. Additional assessments will include the incidence of AMS, headache characteristics, safety outcomes, vital signs, oxygen saturation, and the use of rescue medication. Symptoms will be assessed repeatedly during the high-altitude stay.
Only healthy adults aged 18 to 60 years living below 1000 meters will be eligible. People with important medical conditions, chronic headache or migraine, relevant cardiovascular or lung disease, pregnancy, or recent high-altitude exposure will be excluded. Participants will be closely monitored during the study. Rescue medication, oxygen, and descent to lower altitude will be available if needed.
This study may help improve understanding of how AMS develops and whether CGRP blockade could become a new preventive strategy for high-altitude headache and AMS. It may also improve understanding of links between altitude-related headache and migraine.

Start Date01 Jun 2027

Sponsor / Collaborator

Insel Gruppe AG

NCT07832266

/ Not yet recruitingPhase 1

Proactively Intervening On Early Cranial Nerve Injury As A Delayed Sequela Of Oropharyngeal Cancer: A Randomized Feasibility Clinical Trial For Pro-Habilitation (proNERVE RCT)

The goal of this clinical research study is to learn about possible intervention strategies to help control cranial neuropathy in patients after they receive radiation therapy for OPC. Four (4) strategies will be tested in this study: 1) high-dose corticosteroid therapy, 2) treatment with fremanezumab, 3) manual tongue exercise therapy, and 4) device-assisted tongue exercise therapy.

Start Date01 Mar 2027

Sponsor / Collaborator-

NCT07029126

/ CompletedNot Applicable

Improving the Perception of Stress and Mutuality in Caregivers (MI-DEAR Study) of Migraine Patients With Depressive Symptoms Treated With Fremanezumab: A Prospective Real-life Observational Study to Evaluate Whether Fremanezumab Reduces the Impact on Caregivers and Increases Couple Reciprocity

To evaluate the reduction of emotional burden (measured by Relative Stress Scale-RSS) of caregivers of migraine patients with Depressive Symptoms after 6 months after the first injection of fremanezumab.

Start Date03 Oct 2024

Sponsor / Collaborator

Fondazione Policlinico Universitario Campus Bio-Medico

[+1]

100 Clinical Results associated with Fremanezumab-VFRM

100 Translational Medicine associated with Fremanezumab-VFRM

100 Patents (Medical) associated with Fremanezumab-VFRM

517

Literatures (Medical) associated with Fremanezumab-VFRM

01 Sep 2026·ADVANCES IN THERAPY

Evaluating the Complementary Nature of Randomized Controlled Trials and Real-World Evidence Using Over 5 Years of Experience with Fremanezumab: A Narrative Review

Review

Author: Ling, Caroline ; Smith, Timothy ; Barbanti, Piero ; Guevara Morel, Alejandra Elizabeth ; Leonard, Caoimhe ; Stark, Richard James ; Bhogal, Preet ; Ramirez Campos, Verena

INTRODUCTION:

Since the pivotal phase 3 randomized controlled trials (RCTs) and regulatory approval of fremanezumab, a calcitonin gene-related peptide (CGRP) monoclonal antibody (mAb) for migraine prevention, several real-world evidence (RWE) studies have been conducted. In this narrative review, we highlight the complementary value of RCTs and RWE studies, by examining > 6 years of fremanezumab efficacy and effectiveness data.

METHODS:

Embase, MEDLINE, MEDLINE In-Process, and Cochrane databases, bibliographies, and conference materials were searched for published RCT data and RWE on efficacy and effectiveness outcomes for fremanezumab. Electronic database and conference abstract searches were limited to articles published between January 2017 and September 2023, and January 2022 and September 2023, respectively.

RESULTS:

Of 48 publications identified for inclusion, 14 reported data from 10 RCTs and 34 reported data from 23 RWE studies. RCTs were of 8-12 weeks duration (with open-label extensions up to 52 weeks) and generally excluded individuals receiving preventive migraine treatment at baseline, and those with previous preventive treatment failures, previous exposure to CGRP pathway mAbs, or severe comorbidities. Exceptions were the UNITE study, which included participants with migraine and major depressive disorder, and the FOCUS studies, which included those with ≥ 2 prior preventive therapies. Most RWE studies included a broader population than RCTs, and were ≥ 3 months long, with some following participants for up to 2 years. Across RCTs, RWE studies, and population subgroup analyses, fremanezumab was consistently associated with improvements in monthly migraine and headache days, from as early as 4 weeks and sustained for up to 52 weeks.

CONCLUSION:

While RCTs and RWE studies have differing strengths and weaknesses, these evidence-generation approaches have together highlighted the potential benefit of fremanezumab for preventive migraine treatment among broad, heterogenous patient populations.

01 Aug 2026·Pain and Therapy

Real-World Characteristics and Treatment Patterns of Calcitonin Gene-Related Peptide Monoclonal Antibody Users: a Japanese Claims Database-Based Study

Article

Author: Miki, Yasuhiro ; Takizawa, Tsubasa ; Hashimoto, Chie ; Ueda, Kaname ; Takemura, Ryo

INTRODUCTION:

Understanding real-world calcitonin gene-related peptide monoclonal antibodies' (CGRP mAbs) use in patients with migraine is necessary to potentially guide treatment strategies.

METHODS:

This retrospective cohort study analyzed administrative claims data from the IQVIA claims data for Japan. It included CGRP mAb-naïve individuals with confirmed migraine diagnosis and ≥ 1 CGRP mAb prescription (January 2021-June 2023). Index date was the first CGRP mAb prescription. Patient characteristics, treatment patterns, adherence (proportion of days covered ≥ 0.80), persistence, and migraine-related direct costs were assessed. Persistence was measured as the proportion of patients continuing treatment for ≥ 3 or ≥ 6 months (≤ 90-day gap between fills). Factors predicting adherence to CGRP mAb treatment were assessed using multivariate logistic regression. Subgroup analyses were conducted for galcanezumab users.

RESULTS:

Of the 1781 patients included (mean age 41.8 years [standard deviation, SD 10.3]; 79.3% female patients), 55.0% received galcanezumab, followed by fremanezumab (29.7%), and erenumab (15.3%). The prescription rates of concomitant acute and oral preventive medications were 86.1% and 51.3%, respectively, in the first 3 months after initiating CGRP mAb treatment but numerically decreased to 49.8% and 22.5%, respectively, in the fourth to sixth month. The index CGRP mAb persistence rates were 91.9% for ≥ 3 months and 76.9% for ≥ 6 months, and adherence rate was 51.7%. Multiple positive and negative predictors of adherence to CGRP mAbs were observed. Index to 3 months after initiating index CGRP mAbs, the median average monthly migraine-related costs were JPY 75,320 (Q1, Q3 61,593, 89,843) (USD 592), and non-CGRP mAb migraine-related costs were JPY 15,702 (Q1, Q3 8845, 27,848) (USD 123). These costs tended to reduce or plateau for up to 12 months thereafter. The galcanezumab subgroup showed a similar trend.

CONCLUSIONS:

CGRP mAb adherence and ≥ 6 months persistence rates were 51.7% and 76.9%, respectively, in CGRP mAb-initiating adults with migraine in Japan. During CGRP mAb treatment, acute and oral preventive medication prescription rates appeared to reduce, while direct costs initially increased but appeared to reduce from the post-initiation peak and plateau over time, although the underlying reasons could not be determined from claims data.

03 Jul 2026·Expert Review of Neurotherapeutics

Fremanezumab for migraine in clinical practice: a systematic review and meta-analysis

Review

Author: Fernández-Bravo-Rodrigo, Jaime ; Martínez-García, Irene ; Saz-Lara, Alicia ; Flor-García, Amparo ; Pascual-Morena, Carlos ; Cavero-Redondo, Iván ; Lever-Megina, Carla Geovanna ; Patiño-Cardona, Silvana

INTRODUCTION:

Although the efficacy of fremanezumab in treating migraine has been proven in randomized controlled trials, its effectiveness is not well understood. Consequently, this study purpose was to synthesize and estimate its real-world effectiveness and safety in patients with migraine.

METHODS:

A systematic search of PubMed, Scopus and Web of Science was conducted from inception to November2025. Real-world studies evaluating fremanezumab effectiveness, measured by monthly migraine days (MMDs), monthly headache days (MHDs), Headache Impact Test (HIT-6) and related outcomes, including safety, were included. Random-effects meta-analyses were performed.

RESULTS:

One month after treatment initiation, fremanezumab reduced MMD by -5.82 days (95% CI: -6.67, -4.97), MHD by -7.30 days (95% CI: -9.72, -4.87) and HIT-6 scores by -6.84 points (95% CI: -10.30, -3.39). Approximately 50% of patients achieved a ≥ 50% reduction in MMD or MHD within 3 months, with response rates increasing progressively up to 12 months. Adverse event rates were 0.05 (95% CI: 0.02, 0.09) in 6 months and 0.07 (95% CI: 0.03, 0.12) in 12 months, with constipation being the most frequently reported event.

CONCLUSION:

Fremanezumab is associated with clinically significant reductions in migraine frequency, disability and acute medication used in real-world settings, with a favorable safety profile.

PROSPERO:

CRD42021266322.

138

News (Medical) associated with Fremanezumab-VFRM

14 Sep 2026

·www.biospace.com

Teva Begins Trading Ordinary Shares Directly on the NYSE, Marking a Milestone in its Pivot to Growth Strategy

Teva Begins Trading Ordinary Shares Directly on the NYSE Teva Pharmaceutical Industries Ltd Begins Trading Ordinary Shares Directly on the NYSE, Marking a Milestone in its Pivot to Growth Strategy PARSIPPANY, N.J. and TEL AVIV, Israel, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), a global biopharmaceutical company, today announced that its ordinary shares will begin trading today directly on the New York Stock Exchange (NYSE) completing the company’s planned transition from its American Depositary Shares (ADSs) program. Teva’s shares continue to trade under the same ticker symbol “TEVA” on both the NYSE and the Tel Aviv Stock Exchange (TASE). “Today marks another meaningful milestone in Teva’s transformation,” said Richard Francis, President and CEO of Teva. “The trading of our ordinary shares on the NYSE is expected to broaden investor access to our shares and reflects the momentum we are building through our Pivot to Growth strategy. We remain focused on delivering for patients, driving sustainable growth, and accelerating our transformation into a leading innovative biopharmaceutical company.” “Our move to a direct ordinary share listing is an important step in strengthening our position in the U.S. capital markets,” said Eli Kalif, Executive Vice President, and Chief Financial Officer of Teva . “Together with our recent return to investment-grade credit ratings from all three major ratings agencies, this milestone demonstrates the strength of our financial transformation, expands our access to investors and enhances our ability to invest for long-term growth.” Teva’s direct listing comes as the company continues to deliver against its Pivot to Growth strategy, transforming into a leading biopharmaceutical company, driven by a fast-growing innovative medicines portfolio and powered by a leading generics business. Year to date its three flagship innovative brands, AUSTEDO ® , AJOVY ® , and UZEDY ® , have grown collectively by more than 40% year-over-year*, with expected 2026 revenues of approximately $3.7 billion. Investment-grade ratings across all three major agencies further underscore Teva’s financial strength, disciplined execution, and continued debt reduction. With multiple near-term pipeline and commercial catalysts ahead, including an innovative pipeline with a potential of more than $10 billion in peak revenues, Teva is well positioned to expand margins, grow earnings and create significant long-term shareholder value. About Teva Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars, and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All in for Better Health . To learn more about how, visit . Cautionary Note Regarding Forward Looking Statements This Press Release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. These forward-looking statements include statements concerning our plans, strategies, objectives, and any other information that is not historical information. You can identify these forward-looking statements by the use of words such as “will,” “should,” “expect,” “anticipate,” “may,” “project,” “intend,” “plan,” “believe,” “transition” and other words and terms of similar meaning and expression in connection with any discussion of future performance developments. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully implement the process for terminating our ADS program and directly list our ordinary shares in lieu of the ADSs on the NYSE and to achieve our aims as a result of such process, as described in Part II, Item 5 of our Quarterly Report on Form 10-Q for the second quarter of 2026; our ability to successfully execute on our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and to profitably commercialize our innovative medicines and biosimilar portfolio, whether organically or through business development, to sustain and focus our portfolio of generic medicines, and to execute on our organizational transformation and to achieve expected cost savings; our significant indebtedness, which may limit our ability to attract investors, incur additional indebtedness, engage in additional transactions or make new investments; and other factors discussed in our Quarterly Report on Form 10-Q for the second quarter of 2026 and in our Annual Report on Form 10-K for the year ended December 31, 2025, including in the sections captioned “Risk Factors” and “Other Information.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements. Teva Media Inquiries: TevaCommunicationsNorthAmerica@tevapharm.com Teva Investor Relations Inquiries: TevaIR@Tevapharm.com *As reported in our Q2 2026 financial results A photo accompanying this announcement is available at

29 Jul 2026

·firstwordpharma.com

Teva's Q2 print paints rosy outlook for innovative portfolio

Shares in Teva Pharmaceuticals jumped close to 10% on Wednesday after the Israeli drugmaker shared that growth for its innovative products segment managed to nearly offset slowing generic sales for the second quarter.The company reported that global revenues from its generic medicines, based on local currency, fell 15% year-over-year for the three month period. The drop-off was linked to lower sales in the US for its generic version of Bristol Myers Squibb's cancer drug Revlimid (lenalidomide).Despite the disappointing results for its generic business, Teva's total second-quarter revenues only slipped 3% in local currency — or 1% in US dollars — compared with 2025 to hit $4.14 billion, beating consensus estimates of $4.05 billion. Helping to stabilise the company's revenues were a trio of innovative medicines that collectively saw their sales grow 43% year-over-year to $1 billion in local currency: Austedo ($696 million, +40%), approved to treat tardive dyskinesia and chorea related to Huntington's disease; migraine medicine Ajovy ($244 million, +56%); and Uzedy ($77 million, +43%), a treatment for schizophrenia and bipolar disorder. The sales uptick prompted Teva to raise its full-year guidance for each product. It now expects combined 2026 revenues of $3.7 billion, representing a 17% year-over-year growth. Specifically, the drugmaker is projecting $2.45-$2.6 billion in full-year sales for Austedo, up from earlier expectations of $2.4-$2.55 billion; $850-$870 million in sales for Ajovy, increased from $750-$790 million; and a sales range of $270-$290 million for Uzedy, up from $250-$280 million.CEO Richard Francis said the financial results demonstrate that the three products are "continuing to transform Teva’s portfolio mix and financial profile."The positive growth figures come as Teva has turned to its innovative medicines segment to fuel its "Pivot to Growth" strategy. Last quarter, the company bought Emalex Biosciences and its late-stage Tourette syndrome candidate ecopipam for $700 million upfront; Teva has since submitted a marketing application with the FDA.Internally, Teva is also advancing duvakitug, an anti-TL1A mAb with positive data in ulcerative colitis and Crohn's disease, as well as TEV-'408, an IL-15–targeting mAb for vitiligo (see – KOL Views Q&A: Teva, Sanofi's anti-TL1A will compete in IBD but Spyre eyeing bigger prize and KOL Views Q&A: Anti-IL-15 therapies from Forte, Teva have game-changing potential in vitiligo).For its total 2026 revenue projection, Teva raised its outlook to $16.5-$16.85 billion, slightly above prior expectations of $16.4-$16.8 billion.

Drug ApprovalFinancial StatementBiosimilarAcquisition

29 Jul 2026

·www.biospace.com

Teva Delivers Strong Q2 Results and Raises Outlook for All Three Key Innovative Brands, Reflecting Continued Execution of Its Pivot to Growth Strategy

Q2 2026 revenues of $4.1 billion decreased by 1% in U.S. dollars year-over-year (YoY) and by 3% in local currency (LC) terms, mainly due to lower generics revenues. Our key innovative brands collectively grew 43% YoY in LC, to over $1 billion in revenues, and we raised our 2026 outlook for all three, highlighting Teva’s continued execution of its Pivot to Growth strategy. Key Innovative brands continued to drive growth while transforming Teva’s portfolio mix and financial profile: AUSTEDO ® continued to grow rapidly, with global revenues of $696 million, growing 40% YoY in LC. AJOVY ® global revenues of $244 million, increasing 56% YoY in LC. UZEDY ® revenues of $77 million, increasing 43% YoY in LC. UZEDY continues to be the fastest growing LAI amongst atypical LAI’s for schizophrenia, creating a strong foundation for Teva's schizophrenia franchise. 1 Teva is raising its 2026 revenue outlook for each of these key innovative brands, and now expects combined 2026 revenue of ~$3.7 billion reflecting a ~17% YoY growth at the mid-point. Generics Powerhouse: generics global revenues were lower in Q2 2026 vs. Q2 2025, mainly due to lower revenues from lenalidomide capsules (a generic version of Revlimid ® ) in the U.S.; biosimilars portfolio performed strongly and on track to deliver $800 million in revenues by 2027. Global generics revenues decreased by 15% YoY in LC, mainly due to lower revenues in our U.S. Segment from lenalidomide capsules (a generic version of Revlimid ® ) due to increased generic competition in the U.S. Biosimilars momentum continues with strategic collaborations and Europe launches: Teva launched AHZANTIVE ® (aflibercept), a biosimilar to Eylea ® , in Europe; Global licensing agreement announced with Polpharma Biologics for a proposed biosimilar to Ocrevus ® (ocrelizumab). Innovative late-stage pipeline progressing at speed, addressing high unmet need : ecopipam: the acquisition of Emalex Biosciences (Emalex) and its primary asset, ecopipam (EBS-101), a first-in-class therapy for Tourette syndrome, for approximately $700 million in cash, reflects the acceleration of our late-stage innovative neuroscience pipeline, in line with Teva's Pivot to Growth Strategy; a New Drug Application for ecopipam was submitted to the U.S. FDA in June 2026, and expenses of $726 million for this acquisition were recorded in Q2 2026, as further described below. olanzapine LAI: in May 2026, the European Medicines Agency (EMA) accepted Teva’s Marketing Authorization Application (MAA) for olanzapine LAI for the treatment of schizophrenia in adults; on track for launch in the U.S. in Q4 2026, subject to regulatory approval. TEV-’408 (anti-IL-15): encouraging Phase 1b results in vitiligo for this Teva-discovered antibody designed for quarterly subcutaneous dosing; initiation of a Phase 2 study expected in Q4 2026. duvakitug (anti-TL1A, developed in collaboration with Sanofi): announced plans to initiate studies in two additional indications – hidradenitis suppurativa (HS) and fibrostenotic Crohn’s Disease (FSCD) – demonstrating its pipeline-in-a-product potential. Recruitment is on track for our Phase 3 studies for duvakitug in ulcerative colitis (UC) and Crohn’s disease (CD). Continuing to transform and modernize our business through the Teva Transformation programs, which combined with innovative product growth potential, is expected to support the Company’s objective of achieving a 30% non-GAAP operating income margin by 2027 and approximately $700 million of net savings by 2027. Teva announces the replacement of its American Depositary Share (ADS) program with the direct listing of its ordinary shares on the New York Stock Exchange (NYSE). ADSs will be exchanged on a one-for one-basis for our ordinary shares, which commence trading on the NYSE on Monday, September 14, 2026 after the ADSs cease trading on the NYSE at the close of trading on Friday, September 11, 2026. The transition aims to broaden Teva’s shareholder base, support its potential inclusion in leading indices, and optimize cost-of-capital. There is no impact to Teva’s ordinary shares traded on the Tel Aviv Stock Exchange (TASE). For more information, see our website at ir.tevapharm.com and Part II, Item 5 of our Quarterly Report on Form 10-Q for the second quarter of 2026 when available. Q2 2026 Highlights: Revenues of $4.1 billion GAAP loss per share of $0.49, of which $726 million of expenses are attributable to Emalex ($724 million of IPR&D and $2 million of operating expenses), or a loss of $0.61 per share Non-GAAP diluted EPS of $0.02, that includes a per share impact of ($0.61) from the Emalex acquisition Cash flow generated from operating activities of $411 million Free cash flow of $622 million 2026 Business Outlook – key innovative brands revenues outlook increased; earnings and cash flow maintained: Revenues of $16.5 - $16.85 billion Non-GAAP operating income of $3.8 - $4.0 billion, including ~$0.77 billion of expected 2026 expenses related to Emalex Adjusted EBITDA of $4.23 - $4.53 billion, including ~$0.77 billion of expected 2026 expenses related to Emalex Non-GAAP diluted EPS of $1.91 - $2.11, including ($0.66) per share of 2026 Emalex expenses. Free cash flow of $2.0 - $2.4 billion ________________ 1 Source: IQVIA NPA 2Q26 vs 2Q25 (TRx normalized into patient months of therapy equivalent volume based on dosing regimen). TEL AVIV, Israel, July 29, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the quarter ended June 30, 2026. ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); Mr. Richard Francis, Teva's President and CEO, said : “Our second quarter reflects continued execution of our Pivot to Growth strategy. During the quarter, and into July, we advanced several value-creating assets, including two additional indications for duvakitug, demonstrating its pipeline-in-a-product potential, the acquisition and NDA submission of ecopipam (EBS-101), continued progress for olanzapine LAI, and expansion of our biosimilars pipeline through strategic collaborations." Mr. Francis added , "Our key Innovative brands collectively generated over $1 billion in revenues, continuing to transform Teva’s portfolio mix and financial profile. The breadth of these milestones underscores the increasingly diversified nature of Teva’s growth profile. We are strengthening our neuroscience and immunology pipeline, expanding access through biosimilars, and continuing to modernize the business to support sustainable, innovation-driven growth and long-term value creation for patients and shareholders.” Pivot to Growth Strategy In the second quarter of 2026, we continued to execute on the four key pillars of our “Pivot to Growth” strategy, announced in May 2023: Delivering on our growth engines - Teva’s key innovative brands, AUSTEDO, AJOVY and UZEDY, collectively grew 43% YoY in LC in Q2 2026 to over $1 billion in revenues, continuing to transform the Company’s portfolio mix and financial profile. Each individual brand grew at least 40% YoY in LC in the quarter. Based on year-to-date performance, Teva is raising its outlook for all three key innovative brands. Stepping up innovation - We advanced multiple assets in our late-stage innovative pipeline focused on well characterized compounds and validated disease targets. Teva submitted an NDA for ecopipam (EBS-101), a first-in-class investigational therapy for pediatric Tourette syndrome, acquired with Emalex. In May 2026, the EMA accepted the MAA for olanzapine LAI (TEV-’749). We announced encouraging Phase 1b results for TEV-’408 (anti-IL-15) in vitiligo and expect to initiate a vitiligo Phase 2 trial in Q4 2026. For duvakitug (anti-TL1A, developed in collaboration with Sanofi) we announced plans to initiate studies in two additional indications – hidradenitis suppurativa (HS) and fibrostenotic Crohn’s Disease (FSCD) – demonstrating its pipeline-in-a-product potential. Recruitment is on track for our Phase 3 studies for duvakitug in ulcerative colitis (UC) and Crohn’s disease (CD). Sustaining our generics powerhouse - Teva continues to enhance its biosimilars portfolio, including the launch of AHZANTIVE ® in Europe and the collaboration agreement with Polpharma Biologics for a proposed biosimilar to Ocrevus ® covering both intravenous and subcutaneous formulations. On track with operational readiness for 3 additional biosimilars in 2027, building a robust portfolio of 18 biosimilars. Focusing our business - We are actively transforming and modernizing our business through Teva Transformation programs and expect to realize two-thirds of the targeted savings in 2026, while maintaining disciplined capital allocation. During the quarter, Fitch Rating Agency raised the Company's corporate credit rating to Investment Grade BBB-, recognizing Teva’s significantly improved balance sheet and successful execution of its Pivot to Growth strategy. Second Quarter 2026 Consolidated Results Revenues in the second quarter of 2026 were $4,142 million, a decrease of 1% in U.S. dollars, or 3% in local currency terms compared to the second quarter of 2025. This decrease was mainly due to lower revenues from generic products, primarily lenalidomide capsules (a generic version of Revlimid ® ) in our U.S. segment, partially offset by higher revenues from our key innovative products, primarily AUSTEDO and AJOVY. Exchange rate movements in the second quarter of 2026 including hedging effects, positively impacted revenues by $85 million, compared to the second quarter of 2025. Gross profit in the second quarter of 2026 was $2,153 million, an increase of 2% compared to $2,102 million in the second quarter of 2025. Gross profit margin was 52.0% in the second quarter of 2026, compared to 50.3% in the second quarter of 2025. This increase was mainly due to higher revenues from AUSTEDO, partially offset by lower revenues from generic products in our United States segment, primarily lenalidomide capsules (a generic version of Revlimid ® ). Non-GAAP gross profit was $2,293 million in the second quarter of 2026, an increase of 1% compared to $2,278 million in the second quarter of 2025. Non-GAAP gross profit margin was 55.4% in the second quarter of 2026, compared to 54.6% in the second quarter of 2025. The increase in both gross profit margin and non-GAAP gross profit margin was mainly due to a favorable mix of products, primarily higher revenues from AUSTEDO and AJOVY, partially offset by lower revenues from generic products, primarily lenalidomide capsules (a generic version of Revlimid ® ). Research and Development (R&D) expenses, net in the second quarter of 2026, were $970 million, an increase of 298% compared to $244 million in the second quarter of 2025, primarily due to our acquisition of Emalex Biosciences and its primary asset, ecopipam (EBS-101). This increase was partially offset by a decrease in our expenses related to our generic projects. Our R&D expenses, net in the second quarters of 2026 and 2025, were also impacted by reimbursements and cost sharing from our strategic partnerships and collaborations entered into in recent years. Selling and Marketing (S&M) expenses in the second quarter of 2026 were $717 million, an increase of 10% compared to the second quarter of 2025. This increase was mainly due to promotional activities related to our key innovative products, primarily AUSTEDO, as well as a negative impact from exchange rate fluctuations. General and Administrative (G&A) expenses in the second quarter of 2026 were $317 million, an increase of 4% compared to the second quarter of 2025. Operating loss was $231 million in the second quarter of 2026, compared to an operating income of $455 million in the second quarter of 2025. Operating loss as a percentage of revenues was 5.6% in the second quarter of 2026, compared to operating income as a percentage of revenues of 10.9% in the second quarter of 2025. This change was mainly due to higher R&D expenses primarily related to the acquisition of Emalex and its primary asset ecopipam (EBS-101). Non-GAAP operating income in the second quarter of 2026 was $375 million representing a non-GAAP operating margin of 9.0% compared to $1,133 million representing 27.1%, respectively, in the second quarter of 2025. This decrease in non-GAAP operating margin in the second quarter of 2026 was mainly due to higher R&D expenses primarily related to the acquisition of ecopipam (EBS-101), as discussed above. Exchange rate movements in the second quarter of 2026, net of hedging effects, had a positive impact of $26 million on our operating loss and non-GAAP operating income compared to the second quarter of 2025. Financial expenses, net in the second quarter of 2026, were $224 million, mainly comprised of net interest expenses of $195 million. In the second quarter of 2025, financial expenses, net were $252 million, mainly comprised of net interest expenses of $203 million. In the second quarter of 2026, we recognized a tax expense of $121 million, on pre-tax loss of $455 million. In the second quarter of 2025, we recognized a tax benefit of $78 million, on pre-tax income of $203 million. Our tax rate in the second quarter of 2026 was negative 26.5%, compared to negative 38.4% in the second quarter of 2025. Non-GAAP tax rate in the second quarter of 2026 was 86.7%, compared to 16.4% in the second quarter of 2025. Our tax rate and non-GAAP tax rate in the second quarter of 2026 were mainly affected by an unfavorable tax impact of a non-deductible acquired IPR&D charge related to the acquisition of Emalex and its primary asset ecopipam (EBS-101), the generation of profits in various jurisdictions in which tax rates are different than the Israeli tax rate and other infrequent or non-recurring items. Our tax rate and non-GAAP tax rate in the second quarter of 2025 were mainly affected by releases of uncertain tax positions, foreign exchange impact on deferred tax positions and interest and inflation adjustments related to the agreement with the Israeli Tax Authorities. Considering the above, we expect our annual non-GAAP tax rate for 2026 to be between 20%-23%, higher than our non-GAAP tax rate for 2025, which was 15.8%. Net loss attributable to Teva and loss per share in the second quarter of 2026 were $576 million and $0.49, respectively, compared to net income attributable to Teva and earning per share of $282 million and $0.24, respectively, in the second quarter of 2025. This change was mainly due to the change in operating loss as well as higher income taxes, primarily due to the acquisition of Emalex and its primary asset, ecopipam (EBS-101), as discussed above. Non-GAAP net income attributable to Teva and non-GAAP diluted earnings per share in the second quarter of 2026 were $21 million and $0.02, respectively, compared to $769 million and $0.66, respectively, in the second quarter of 2025. Adjusted EBITDA was $474 million in the second quarter of 2026, a decrease of 62%, compared to $1,233 million in the second quarter of 2025. As of June 30, 2026 and 2025, the fully diluted share count for purposes of calculating our market capitalization was approximately 1,191 million shares and 1,179 million shares, respectively. Non-GAAP information : non-GAAP adjustments in the second quarter of 2026 were $597 million. Non-GAAP net income attributable to Teva and non-GAAP diluted EPS for the second quarter of 2026 were adjusted to exclude the following items: Amortization of purchased intangible assets of $139 million, of which $129 million is included in cost of sales and the remaining $9 million in S&M expenses; Legal settlements and loss contingencies of $230 million; Restructuring expenses of $38 million; Impairment of long-lived assets of $113 million; Contingent consideration expenses of $17 million; Equity compensation expenses of $40 million; Financial expenses of $8 million; Other non-GAAP items of $29 million; and Corresponding tax effects and unusual tax items of $17 million. We believe that excluding such items facilitates investors’ understanding of our business including underlying trends, thereby improving the comparability of our business performance results between reporting periods. For a reconciliation of the U.S. GAAP results to the adjusted non-GAAP figures and for additional information, see the tables below and the information included under “Non-GAAP Financial Measures.” Investors should consider non-GAAP financial measures in addition to, and not as replacement for, or superior to, measures of financial performance prepared in accordance with GAAP. Cash flow generated from operating activities during the second quarter of 2026 was $411 million compared to $227 million in the second quarter of 2025. The higher cash flow generated from operating activities in the second quarter of 2026 was mainly due to lower contingent consideration payments and lower tax payments, partially offset by higher legal settlement payments. During the second quarter of 2026, we generated free cash flow of $622 million, which we define as comprising: $411 million in cash flow generated from operating activities, $311 million in beneficial interest collected in exchange for securitized accounts receivables (under our EU securitization program) and $4 million of proceeds from the sale of businesses and long-lived assets, partially offset by $104 million in cash used for capital investments. During the second quarter of 2025, we generated free cash flow of $476 million, which we define as comprising $227 million in cash flow generated from operating activities, $336 million in beneficial interest collected in exchange for securitized accounts receivables (under our EU securitization program) and $9 million of proceeds from the sale of businesses and long-lived assets, partially offset by $96 million in cash used for capital investments. The increase in the second quarter of 2026 resulted mainly from higher cash flow generated from operating activities, as discussed above. As of June 30, 2026, our debt was $16,593 million, compared to $16,807 million as of December 31, 2025. This decrease was mainly due to $201 million of exchange rate fluctuations. The portion of total debt classified as short-term as of June 30, 2026, was 27% compared to 11% as of December 31, 2025. Our financial leverage, which is the ratio between our debt and the sum of our debt and equity, was 68% as of June 30, 2026 and December 31, 2025. Our average debt maturity was approximately 5.1 years as of June 30, 2026, compared to 5.6 years as of December 31, 2025. Segment Results for the second quarter of 2026 United States Segment In alignment with our Pivot to Growth strategy, commencing January 1, 2026, Anda is no longer reported under our United States segment. This shift allows the United States segment to continue to manage its entire product portfolio in the region, while strengthening focus on its biopharmaceutical business, growth engines and innovation. As a result, from that date, Anda is reported as part of the Company’s Other Activities. Prior period amounts were recast to reflect this change. The following table presents revenues, expenses and profit for our United States segment for the three months ended June 30, 2026 and 2025: Three months ended June 30, 2026 2025 (U.S. $ in millions / % of Segment Revenues) Revenues $ 1,702 100 % $ 1,786 100 % Cost of sales 499 29.3 % 574 32.2 % Gross profit 1,203 70.7 % 1,211 67.8 % R&D expenses * 883 51.9 % 152 8.5 % S&M expenses 294 17.3 % 250 14.0 % G&A expenses 107 6.3 % 111 6.2 % Other (5 ) § § § Segment profit (loss) * * $ (76 ) (4.5 %) $ 699 39.1 % * Mainly related to the acquisition of Emalex and its primary asset ecopipam (EBS-101) in the United States segment. ** Segment profit does not include amortization and certain other items. § Represents an amount less than $0.5 million or 0.5%, as applicable. Revenues from our United States segment in the second quarter of 2026 were $1,702 million, a decrease of 5% compared to the second quarter of 2025, mainly due to lower revenues from generic products, primarily lenalidomide capsules (a generic version of Revlimid ® ), partially offset by higher revenues from our key innovative products, primarily AUSTEDO. Revenues by Major Products and Activities The following table presents revenues for our United States segment by major products and activities for the three months ended June 30, 2026 and 2025: Three months ended June 30, Percentage Change 2026 2025 2026-2025 (U.S. $ in millions) Generic products (including biosimilars) $ 660 $ 961 (31%) AJOVY ® 116 63 83% AUSTEDO 676 495 37% BENDEKA ® and TREANDA ® 28 40 (30%) COPAXONE ® 61 62 (2%) UZEDY 77 54 43% Other 84 111 (25%) Total $ 1,702 $ 1,786 (5%) Generic products (including biosimilar products) revenues in our United States segment in the second quarter of 2026 were $660 million, a decrease of 31% compared to the second quarter of 2025. This decrease was mainly driven by lower revenues from lenalidomide capsules (a generic version of Revlimid ® ) due to increased generic competition in the U.S., partially offset by higher revenues from our portfolio of biosimilar products. Among the most significant generic products we sold in the United States in the second quarter of 2026 were Truxima ® (a biosimilar to Rituxan ® ), epinephrine injectable solution (a generic equivalent of EpiPen ® and EpiPen Jr ® ) and SIMLANDI ® (a biosimilar to Humira ® ). In the second quarter of 2026, our total prescriptions were approximately 237 million (based on trailing twelve months), representing 6.1% of total U.S. generic prescriptions, compared to approximately 266 million (based on trailing twelve months), representing 6.9% of total U.S. generic prescriptions in the second quarter of 2025, all according to IQVIA data. AJOVY revenues in our United States segment in the second quarter of 2026 were $116 million, an increase of 83% compared to the second quarter of 2025, mainly due to a reduction in sales allowance as well as growth in volume. In the second quarter of 2026, AJOVY’s exit market share in the United States in terms of total number of prescriptions was 32.5% out of the subcutaneous injectable anti-CGRP class, compared to 31.0% in the second quarter of 2025. AUSTEDO revenues (which include AUSTEDO XR ® ) in our United States segment in the second quarter of 2026 were $676 million, an increase of 37%, compared to the second quarter of 2025. This increase was mainly due to growth in volume and a favorable business mix including improved net-price realization. AUSTEDO XR (deutetrabenazine) extended-release tablets was approved by the FDA on February 17, 2023 in three doses of 6, 12 and 24 mg, and became commercially available in the U.S. in May 2023. The FDA approved AUSTEDO XR as a one pill, once-daily treatment option in doses of 30, 36, 42, and 48 mg in May 2024 and in 18 mg in July 2024. AUSTEDO XR is a once-daily formulation indicated in adults for tardive dyskinesia and chorea associated with Huntington’s disease, which is additional to the twice-daily AUSTEDO. UZEDY (risperidone) extended-release injectable suspension revenues in our United States segment in the second quarter of 2026 were $77 million, an increase of 43% compared to the second quarter of 2025, mainly due to growth in volume, partially offset by higher sales allowances. BENDEKA and TREANDA combined revenues in our United States segment in the second quarter of 2026 were $28 million, a decrease of 30% compared to the second quarter of 2025, mainly due to competition from alternative therapies, as well as from branded and generic bendamustine products. COPAXONE revenues in our United States segment in the second quarter of 2026 were $61 million, a decrease of 2% compared to the second quarter of 2025, mainly due to lower volumes, partially offset by a reduction in sales allowance. United States Gross Profit Gross profit from our United States segment in the second quarter of 2026 was $1,203 million, a decrease of 1%, compared to the second quarter of 2025. Gross profit margin for our United States segment in the second quarter of 2026 increased to 70.7%, compared to 67.8% in the second quarter of 2025. This increase was mainly due to a favorable mix of products, primarily due to higher revenues from our key innovative products, largely AUSTEDO, partially offset by lower revenues from lenalidomide capsules (a generic version of Revlimid ® ). United States Profit Profit from our United States segment consists of revenues less cost of sales, R&D expenses, S&M expenses, G&A expenses and other expenses (income) related to this segment. Segment profit does not include amortization and certain other items. Loss from our United States segment in the second quarter of 2026 was $76 million, compared to a profit of $699 million in the second quarter of 2025. This change was mainly due to higher R&D expenses, primarily related to the acquisition of Emalex and its primary asset ecopipam (EBS-101). Europe Segment Our Europe segment includes the European Union, the United Kingdom and certain other European countries. The following table presents revenues, expenses and profit for our Europe segment for the three months ended June 30, 2026 and 2025: Three months ended June 30, 2026 2025 (U.S. $ in millions / % of Segment Revenues) Revenues $ 1,263 100 % $ 1,298 100 % Cost of sales 559 44.3 % 581 44.8 % Gross profit 704 55.7 % 717 55.2 % R&D expenses 52 4.1 % 59 4.6 % S&M expenses 222 17.6 % 228 17.5 % G&A expenses 66 5.2 % 66 5.1 % Other * (3 ) § § § Segment profit * $ 367 29.1 % $ 364 28.0 % * Segment profit does not include amortization and certain other items. § Represents an amount less than $0.5 million or 0.5%, as applicable. Revenues from our Europe segment in the second quarter of 2026 were $1,263 million, a decrease of 3% compared to the second quarter of 2025. In local currency terms, revenues decreased by 8% compared to the second quarter of 2025, mainly due to lower proceeds from the sale of certain product rights, and lower revenues from generic products. In the second quarter of 2026, revenues were positively impacted by exchange rate fluctuations of $63 million, including hedging effects, compared to the second quarter of 2025. Revenues in the second quarter of 2026, included $3 million from a positive hedging impact, while revenues in the second quarter of 2025 included $25 million from a negative hedging impact, which is included in “Other” in the table below. Revenues by Major Products and Activities The following table presents revenues for our Europe segment by major products and activities for the three months ended June 30, 2026 and 2025: Three months ended June 30, Percentage Change 2026 2025 2026-2025 (U.S. $ in millions) Generic products (including OTC and biosimilars) $ 1,024 $ 1,040 (2%) AJOVY 78 71 10% COPAXONE 49 50 (2%) Respiratory products 58 55 6% Other * 54 81 (34%) Total $ 1,263 $ 1,298 (3%) * Other revenues in the second quarter of 2025 include the sale of certain product rights. Generic products revenues (including OTC and biosimilar products) in our Europe segment in the second quarter of 2026, were $1,024 million, a decrease of 2% compared to the second quarter of 2025. In local currency terms, revenues decreased by 4%, mainly due to lower sales of generic products and seasonal OTC products, partially offset by higher revenues from recently launched products. AJOVY revenues in our Europe segment in the second quarter of 2026 were $78 million, an increase of 10%, compared to the second quarter of 2025. In local currency terms revenues increased by 7% due to growth in volume. COPAXONE revenues in our Europe segment in the second quarter of 2026 were $49 million, a decrease of 2% compared to the second quarter of 2025. In local currency terms revenues decreased by 5%, mainly due to price reductions and lower volumes resulting from the availability of alternative therapies, partially offset by a decrease in sales allowance due to a non-recurring item. Respiratory products revenues in our Europe segment in the second quarter of 2026 were $58 million, an increase of 6% compared to the second quarter of 2025. In local currency terms, revenues increased by 3%, mainly due to higher volumes as a result of increased supply. Europe Gross Profit Gross profit from our Europe segment in the second quarter of 2026 was $704 million, a decrease of 2% compared to the second quarter of 2025. Gross profit margin for our Europe segment in the second quarter of 2026 increased to 55.7%, compared to 55.2% in the second quarter of 2025. This increase was mainly due to a positive impact from hedging activities, partially offset by lower proceeds from the sale of certain product rights in the second quarter of 2026. Europe Profit Profit from our Europe segment consists of revenues less cost of sales, R&D expenses, S&M expenses, G&A expenses and other expenses (income) related to this segment. Segment profit does not include amortization and certain other items. Profit from our Europe segment in the second quarter of 2026 was $367 million, an increase of 1%, compared to the second quarter of 2025. International Markets Segment Our International Markets segment includes all countries in which we operate other than the United States and the countries included in our Europe segment. The International Markets segment covers a substantial portion of the global pharmaceutical industry, including more than 35 countries. The countries in our International Markets segment include highly regulated, mainly generic markets, such as Canada and Israel, and branded generics-oriented markets, such as Russia and certain Latin America markets. The following table presents revenues, expenses and profit for our International Markets segment for the three months ended June 30, 2026 and 2025: Three months ended June 30, 2026 2025 (U.S. $ in millions / % of Segment Revenues) Revenues $ 550 100 % $ 495 100 % Cost of sales 266 48.3 % 251 50.8 % Gross profit 284 51.7 % 243 49.2 % R&D expenses 26 4.8 % 24 4.9 % S&M expenses 128 23.3 % 114 23.0 % G&A expenses 38 6.9 % 32 6.6 % Other (8 ) (1.4 %) (1 ) § Segment profit * $ 99 18.0 % $ 74 14.9 % * Segment profit does not include amortization and certain other items. § Represents an amount less than $0.5 million or 0.5%, as applicable. Revenues from our International Markets segment in the second quarter of 2026 were $550 million, an increase of 11% compared to the second quarter of 2025. In local currency terms, revenues increased by 7% compared to the second quarter of 2025, mainly due to higher revenues from our key innovative products AJOVY and AUSTEDO, primarily in China. In the second quarter of 2026, revenues were positively impacted by exchange rate fluctuations of $19 million, net of hedging effects, compared to the second quarter of 2025. Revenues in the second quarter of 2026 included $11 million from a negative hedging impact, compared to a negative hedging impact of $8 million in the second quarter of 2025, which are included in “Other” in the table below. The following table presents revenues for our International Markets segment by major products and activities for the three months ended June 30, 2026 and 2025: Three months ended June 30, Percentage Change 2026 2025 2026-2025 (U.S. $ in millions) Generic products (including OTC and biosimilars) $ 419 $ 410 2% AJOVY 49 20 146% AUSTEDO 20 3 571% COPAXONE 8 7 7% Other * 55 55 (1%) Total $ 550 $ 495 11% *Other revenues in the second quarter of 2025 include the sale of certain product rights. Generic products revenues (including OTC and biosimilar products) in our International Markets segment in the second quarter of 2026 were $419 million, an increase of 2% compared to the second quarter of 2025. In local currency terms, revenues decreased by 1%. AJOVY revenues in our International Markets segment in the second quarter of 2026 were $49 million, an increase of 146% compared to the second quarter of 2025. In local currency terms, revenues increased by 141%, mainly due to milestone payments received in China, as well as growth in other markets. In April 2026, we announced a strategic partnership for the marketing and distribution of AJOVY in China with Nuerogen (Zhuhai) Pharmaceutical Company Ltd. AUSTEDO revenues in our International Markets segment in the second quarter of 2026 were $20 million, compared to $3 million in the second quarter of 2025. This increase was mainly due to timing of shipments, as well as growth in China. COPAXONE revenues in our International Markets segment in the second quarter of 2026 were $8 million, an increase of 7% compared to the second quarter of 2025. International Markets Gross Profit Gross profit from our International Markets segment in the second quarter of 2026 was $284 million, an increase of 17% compared to the second quarter of 2025. Gross profit margin for our International Markets segment in the second quarter of 2026 increased to 51.7%, compared to 49.2% in the second quarter of 2025. This increase was mainly due to higher revenues from AJOVY and AUSTEDO as discussed above. International Markets Profit Profit from our International Markets segment consists of revenues less cost of sales, R&D expenses, S&M expenses, G&A expenses and other expenses (income) related to this segment. Segment profit does not include amortization and certain other items. Profit from our International Markets segment in the second quarter of 2026 was $99 million, an increase of 34%, compared to the second quarter of 2025. This increase was mainly due to higher revenues, as discussed above. Other Activities We have other sources of revenues, primarily our distribution business in the United States through Anda, the sale of APIs to third parties, an out-licensing platform offering a portfolio of products to other pharmaceutical companies through our affiliate Medis and certain contract manufacturing services. Our Other Activities are not included in our United States, Europe or International Markets segments described above. In alignment with our Pivot to Growth strategy, commencing January 1, 2026, Anda is no longer reported under our United States segment. As a result, from that date, Anda is reported as part of our Other Activities. Prior period amounts were recast to reflect this change. In 2024, we announced that we intend to divest our API business (including its R&D, manufacturing and commercial activities) through a sale. The intention to divest is in alignment with our Pivot to Growth strategy, and Teva is conducting a sales process for this matter. However, there can be no assurance regarding the ultimate timing or structure of a potential divestiture or that a divestiture will be completed at all. Our revenues from Other Activities in the second quarter of 2026 were $627 million, an increase of 5% in both U.S. dollars and local currency terms, compared to the second quarter of 2025. Anda revenues from third-party products in the second quarter of 2026 were $413 million, an increase of 13%, compared to the second quarter of 2025, mainly due to higher volumes. Anda, our distribution business in the United States, operates independently and distributes generic and innovative medicines and OTC pharmaceutical products from various manufacturers to independent retail pharmacies, pharmacy retail chains, hospitals and physician offices in the United States. Anda competes in the distribution market by maintaining a broad portfolio of products, competitive pricing and delivery throughout the United States. API sales to third parties in the second quarter of 2026 were $118 million, a decrease of 12% in both U.S. dollars and local currency terms, compared to the second quarter of 2025. This decrease was mainly due to lower demand resulting from market dynamics and price reductions. Revenues from additional other activities, mainly from Medis and certain contract manufacturing services, in the second quarter of 2026 were $95 million, a decrease of 3% in U.S. dollars, or 5% in local currency terms compared to the second quarter of 2025. 2026 Financial Outlook $ billions , except diluted EPS or as noted April 2026 (Including Emalex ) July 29 Outlook (Including Emalex ) Emalex impact Revenues 16.4 - 16.8 $16.5 - $16.85B AUSTEDO ($m) 2,400 - 2,550 2,450 - 2,600 AJOVY ($m) 750 - 790 850 – 870 UZEDY ($m) 250 - 280 270 – 290 Operating Income* 3.8 - 4.0 3.8 - 4.0 (0.77) Adjusted EBITDA* 4.23 – 4.53 4.23 – 4.53 (0.77) Finance Expenses* ~$0.8B ~$0.8B Tax Rate* 20% - 23% 20% - 23% (+400 bps to ETR) Diluted EPS* ($) 1.91 - 2.11 1.91 - 2.11 (0.66) Free Cash Flow* 2.0 - 2.4 2.0 - 2.4 CAPEX 0.5 0.5 Foreign Exchange Volatile swings in FX can negatively impact revenue and income * Certain items above are non-GAAP financial measures. For more information, see “Non-GAAP Financial Measures” below. Free Cash Flow includes cash flow generated from operating activities net of capital expenditures and deferred purchase price cash component collected for securitized trade receivables. Conference Call Teva will host a conference call and live webcast along with a slide presentation on Wednesday, July 29, 2026 at 8:00 a.m. ET to discuss its second quarter 2026 financial results and overall business environment. A question & answer session will follow. In order to participate, please register in advance here to obtain a local or toll‐free phone number and your personal pin. A live webcast of the call will be available on Teva's website at: Following the conclusion of the call, a replay of the webcast will be available within 24 hours on Teva's website. About Teva Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit . Some amounts in this press release may not add up due to rounding. All percentages have been calculated using unrounded amounts Non-GAAP Financial Measures This press release contains certain financial information that differs from what is reported under accounting principles generally accepted in the United States ("GAAP"). These non-GAAP financial measures, including, but not limited to, non-GAAP operating income, non-GAAP operating margin, non-GAAP gross profit, non-GAAP gross profit margin, Adjusted EBITDA, free cash flow, non-GAAP tax rate, non-GAAP net income (loss) attributable to Teva and non-GAAP diluted EPS, are presented in order to facilitate investors' understanding of our business. We utilize certain non-GAAP financial measures to evaluate performance in conjunction with other performance metrics. The following are examples of how we utilize the non-GAAP measures: our management and board of directors use the non-GAAP measures to evaluate our operational performance and, to compare our results against work plans and budgets, and ultimately to evaluate the performance of management; our annual budgets are prepared on a non-GAAP basis; and senior management’s annual compensation is derived, in part, using these non-GAAP measures. See the attached tables for a reconciliation of the GAAP results to the adjusted non-GAAP measures. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. We are not providing the most comparable forward-looking GAAP measures for non-GAAP metrics included in our financial outlook or a quantitative reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP measures because we are unable to predict with reasonable certainty the ultimate outcome of certain significant items including, but not limited to, the amortization of purchased intangible assets, legal settlements and loss contingencies, impairment of long-lived assets and goodwill impairment, without unreasonable effort. These items are uncertain, depend on various factors, and could be material to our results computed in accordance with GAAP. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as “should,” "will", “expect,” "aim", “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe”, "outlook", "transition" and other words and terms of similar meaning and expression in connection with any discussion of future operating financial performance or development. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully compete in the marketplace, including: that we are substantially dependent on our generic products; concentration of our customer base and commercial alliances among our customers; competition faced by our generic medicines from other pharmaceutical companies and changes in regulatory policy that may result in costs and delays; delays in launches of new generic products; our ability to develop and commercialize additional pharmaceutical products in a timely manner; intense competition for our innovative medicines; our ability to achieve expected results from investments in our product pipeline; our ability to successfully execute on our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and to profitably commercialize our innovative medicines and biosimilar portfolio, whether organically or through business development, and to sustain and focus our portfolio of generics medicines, and to execute on our organizational transformation and to achieve expected cost savings; and the effectiveness of our patents and other measures to protect our intellectual property rights; our significant indebtedness, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments; and our potential need to raise additional funds in the future, which may not be available on acceptable terms or at all; our business and operations in general, including: the impact of global economic conditions and other macroeconomic developments and the governmental and societal responses thereto, and our exposure to changes in international trade policies, including the imposition of tariffs in the jurisdictions in which we operate, and any effects of such developments on sales of our products and the pricing and availability of raw materials; effectiveness of our optimization efforts; significant disruptions of information technology systems, including cybersecurity attacks, as well as risks and uncertainties related to the adoption of artificial intelligence technologies, and breaches of our data security; interruptions in our supply chain or problems with internal or third party manufacturing; challenges associated with conducting business globally, including political or economic instability, prolonged government shutdowns, widespread outbreaks of major diseases and major hostilities or acts of terrorism, such as the ongoing conflict in the Middle East and the war involving Iran, and the war between Russia and Ukraine; our ability to attract, hire, integrate and retain highly skilled personnel; our ability to successfully bid for suitable acquisition targets or licensing opportunities, or to consummate and/or integrate acquisitions successfully and cost-effectively; and our prospects and opportunities for growth if we sell or plan to sell assets or business units and close or divest plants and facilities, as well as our ability to successfully and cost-effectively effectuate and consummate such sales and divestitures, including our planned divestiture of our API business; compliance, regulatory and litigation matters, including: failure to comply with complex legal and regulatory requirements, the effects of regulatory uncertainty and changes and the results of increased regulatory oversight, including expenditures required to ensure compliance with research, production and quality control regulations and remedial actions taken to address product issues, such as delayed product launches, product recalls, and facility shutdowns; the effects of governmental, regulatory and civil proceedings and litigation which we are, or in the future become, party to; the effects of reforms in healthcare regulation and related reductions in pharmaceutical pricing, reimbursement and coverage, including as a result of the One Big Beautiful Bill signed into law in the U.S. in July 2025 (“OBBBA”), which will likely reduce the number of insured in Medicaid and Health Insurance Exchange markets, potentially altering utilization patterns and shifting negotiating leverage among payors, U.S. Executive Orders issued in April and May 2025 intended to reduce the prices paid for prescription medicines, including Most-Favored-Nation pricing; legal and regulatory actions in connection with public concern over the abuse of opioid medications; our ability to timely make payments required under our nationwide opioids settlement agreement and provide our generic version of Narcan ® (naloxone hydrochloride nasal spray) in the amounts and at the times required under the terms of such agreement; scrutiny from competition and pricing authorities around the world, including our ability to comply with and operate under our deferred prosecution agreement (“DPA”) with the U.S. Department of Justice (“DOJ”); potential liability for intellectual property right infringement; significant product liability claims; claims brought by regulatory agencies; failure to comply with complex Medicare, Medicaid and other governmental programs’ reporting and payment obligations; compliance with sanctions and trade control laws; environmental risks; and the impact of sustainability issues; financial, economic and other risks, including: our exposure to currency fluctuations and restrictions as well as credit risks; impairments of our long-lived assets; potential significant increases in tax liabilities; the effect on our overall effective tax rate of the termination or expiration of governmental programs or tax benefits, or of a change in our business; the impact of any failure to maintain effective internal control over our financial reporting; our ability to successfully implement the process for terminating our ADS program and directly listing our ordinary shares in lieu of the ADSs (the “Conversion”) and achieve our aims as a result of such Conversion, as further described in Part II, Item 5 our Quarterly Report on Form 10-Q and on our website at ir.tevapharm.com; and other factors discussed in this press release, in our Quarterly Report on Form 10-Q for the second quarter of 2026 and in our Annual Report on Form 10-K for the year ended December 31, 2025, including in the section captioned “Risk Factors,” “Other Information” and “Cautionary Note Regarding Forward-Looking Statements.“ Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements. Consolidated Statements of Income (U.S. dollars in millions, except share and per share data) (Unaudited) Three months ended Six months ended June 30, June 30, 2026 2025 2026 2025 Net revenues 4,142 4,176 8,124 8,067 Cost of sales 1,989 2,074 4,000 4,088 Gross profit 2,153 2,102 4,124 3,979 Research and development expenses 970 244 1,191 490 Selling and marketing expenses 717 654 1,413 1,276 General and administrative expenses 317 305 621 603 Intangible assets impairments 22 42 30 163 Other asset impairments, restructuring and other items 147 232 173 210 Legal settlements and loss contingencies 230 166 303 252 Other loss (income) (19) 4 (28) 9 Operating income (loss) (231) 455 421 975 Financial expenses, net 224 252 440 477 Income (loss) before income taxes (455) 203 (18) 497 Income taxes (benefit) 121 (78) 188 (4) Share in (profits) losses of associated companies, net § (1) 1 (1) Net income (loss) (575) 283 (206) 503 Net income (loss) attributable to redeemable and non-redeemable non-controlling interests § § § 6 Net income (loss) attributable to Teva (576) 282 (207) 497 Earnings (loss) per share attributable to Teva: Basic ($) (0.49) 0.25 (0.18) 0.43 Diluted ($) (0.49) 0.24 (0.18) 0.43 Weighted average number of shares (in millions): Basic 1,165 1,147 1,160 1142 Diluted 1,165 1,161 1,160 1,159 Non-GAAP net income attributable to Teva for diluted earnings per share:* 21 769 642 1,371 Non-GAAP earnings per share attributable to Teva:* Diluted ($) 0.02 0.66 0.54 1.18 Non-GAAP average number of shares (in millions): Diluted 1,181 1,161 1,179 1,159 Amounts may not add up due to rounding. § Represents an amount less than $0.5 million. * See reconciliation attached. CONSOLIDATED BALANCE SHEETS (U.S. dollars in millions, except for share data) (Unaudited) June 30, December 31, 2026 2025 ASSETS Current assets: Cash and cash equivalents $ 3,655 $ 3,556 Accounts receivables, net of allowance for credit losses of $75 million and $81 million as of June 30, 2026 and December 31, 2025, respectively. 3,493 3,709 Inventories 3,221 3,179 Prepaid expenses 1,034 1,122 Other current assets 563 539 Assets held for sale 1,794 1,842 Total current assets 13,760 13,946 Deferred income taxes 2,162 2,191 Other non-current assets 387 405 Property, plant and equipment, net 3,928 4,080 Operating lease right-of-use assets, net 333 345 Identifiable intangible assets, net 3,447 3,781 Goodwill 15,839 16,000 Total assets $ 39,857 $ 40,748 LIABILITIES AND EQUITY Current liabilities: Short-term debt $ 4,500 $ 1,820 Sales reserves and allowances 3,899 4,143 Accounts payables 2,721 2,531 Employee-related obligations 488 739 Accrued expenses 2,738 2,687 Other current liabilities 987 1,182 Liabilities held for sale 313 354 Total current liabilities 15,646 13,456 Long-term liabilities: Deferred income taxes 289 296 Other taxes and long-term liabilities 3,791 3,808 Senior notes and loans 12,092 14,986 Operating lease liabilities 282 288 Total long-term liabilities 16,454 19,379 Equity: Teva shareholders’ equity: 7,753 7,910 Non-controlling interests 4 4 Total equity 7,757 7,914 Total liabilities and equity $ 39,857 $ 40,748 Amounts may not add up due to rounding. TEVA PHARMACEUTICAL INDUSTRIES LIMITED CONSOLIDATED STATEMENTS OF CASH FLOWS (U.S. dollars in millions) (Unaudited) Three months ended Six months ended June 30, June 30, 2026 2025 2026 2025 Operating activities: Net income (loss) $ (575) 283 $ (206) 503 Adjustments to reconcile net income (loss) to net cash provided by operations: Depreciation and amortization 241 251 480 494 Impairment of long-lived assets and assets held for sale 113 99 122 177 Acquired IPR&D related to Emalex Biosciences 724 - 724 - Net change in operating assets and liabilities (164) (336) (780) (1,035) Deferred income taxes – net and uncertain tax positions 25 (211) 3 (183) Stock-based compensation 40 38 83 72 Other items 19 105 (36) 94 Net loss (gain) from sale of business and long-lived assets (12) (2) (20) - Net cash provided by (used in) operating activities 411 227 371 122 Investing activities: Beneficial interest collected in exchange for securitized trade receivables 311 336 665 658 Purchases of property, plant and equipment and intangible assets (104) (96) (273) (223) Proceeds from sale of business and long-lived assets, net 4 9 46 26 Purchase of Emalex Biosciences outstanding shares (696) - (696) - Purchases of investments and other assets . (1) (16) (1) (27) Other investing activities (4) 3 (3) 3 Net cash provided by (used in) investing activities (491) 236 (263) 437 Financing activities: Repayment of senior notes and loans and other long-term liabilities - (2,300) (23) (3,668) Repayment of convertible debentures - 2,305 - 2,305 Purchase of shares from redeemable and non-redeemable non-controlling interests - - - (38) Dividends paid to redeemable and non-redeemable non-controlling interests - - - (340) Other financing activities (1) 1 35 3 Net cash provided by (used in) financing activities (1) 6 12 (1,738) Effect of exchange rate changes on cash and cash equivalents (5) (5) (22) 40 Net change in cash and cash equivalents (86) 464 99 (1,139) Balance of cash and cash equivalents at beginning of period 3,741 1,697 3,556 3,300 Balance of cash and cash equivalents at end of period $ 3,655 2,161 $ 3,655 2,161 Non-cash financing and investing activities: Beneficial interest obtained in exchange for securitized accounts receivables $ 295 329 $ 606 641 Amounts may not add up due to rounding. The accompanying notes are an integral part of the financial statements. Reconciliation of net income (loss) attributable to Teva to Non-GAAP net income (loss) attributable to Teva (Unaudited) Three months ended Six months ended June 30, June 30, ($ in millions except per share amounts) 2026 2025 2026 2025 Net income (Loss) attributable to Teva ($) (576) 282 ($) (207) 497 Increase (decrease) for excluded items: Amortization of purchased intangible assets 139 148 276 292 Legal settlements and loss contingencies (1) 230 166 302 249 Impairment of long-lived assets (2) 113 99 122 177 Restructuring costs (3) 38 154 63 168 Equity compensation 40 38 83 72 Contingent consideration 17 19 22 30 Financial expenses 8 37 21 51 Other non-GAAP items (4) 29 53 41 118 Corresponding tax effects and unusual tax items (5) (17) (228) (82) (283) Non-GAAP net income attributable to Teva ($) 21 769 ($) 642 1,371 Non-GAAP tax rate (6) 86.7% 16.4% 29.6% 16.9% GAAP diluted earnings (loss) per share attributable to Teva ($) (0.49) 0.24 ($) (0.18) 0.43 EPS difference (7) 0.51 0.42 0.72 0.75 Non-GAAP diluted EPS attributable to Teva (7) ($) 0.02 0.66 ($) 0.54 1.18 Non-GAAP average number of shares (in millions) (7) 1,181 1,161 1,179 1,159 (1) For the three and six months ended June 30, 2026, adjustments for legal settlements and loss contingencies mainly consisted of (a) an estimated provision recorded in connection with one of the Company's ongoing antitrust litigations in the amount of $117 million, and (b) an update to the estimated settlement provision for the opioid cases (mainly the effect of the passage of time on the net present value of the discounted payments) in the amount of $49 million and $97 million, respectively. For the three and six months ended June 30, 2025, adjustments of legal settlements and loss contingencies mainly consisted of (a) an update to the estimated settlement provision for the opioid cases (mainly the effect of the passage of time on the net present value of the discounted payments) in the amount of $47 million and $97 million, respectively, and (b) an update to the estimated provision recorded for the claims brought by attorneys general representing states and territories throughout the United States in the generic drug antitrust litigation in the amount of $55 million. (2) The expense for the three and six months ended June 30, 2026, was mainly related to an impairment charge of $70 million in connection with a manufacturing facility in Europe. For the three months ended June 30, 2025, the adjustment for impairment of long-lived assets consisted of (a) impairment of long-lived assets of $42 million mainly related to products in the U.S. and Europe, and (b) $55 million related to the held for sale measurement of the API business (including its R&D, manufacturing and commercial activities), which includes a favorable impact related to the expected gain from the reclassification of currency translation adjustments. For the six months ended June 30, 2025, the adjustment for impairment of long-lived assets was mainly related to products in the U.S. and Europe. (3) In the three and six months ended June 30, 2025, Teva recorded $154 million and $168 million, respectively, of restructuring expenses primarily related to optimization activities in connection with Teva’s Transformation programs related to Teva’s global organization and operations mainly through headcount reduction. (4) Other non-GAAP items include other exceptional items that we believe are sufficiently large that their exclusion is important to facilitate an understanding of trends in our financial results, primarily related to the rationalization of our plants, accelerated depreciation, material litigation fees and other unusual events. (5) Adjustments for corresponding tax effects and unusual tax items exclusively consisted of the tax impact directly attributable to the pre-tax items that are excluded from non-GAAP net income included in the other adjustments to this table. (6) Non-GAAP tax rate is tax expenses (benefit) excluding the impact of non-GAAP tax adjustments presented above as a percentage of income (loss) before income taxes excluding the impact of non-GAAP adjustments presented above. Our non-GAAP tax rate in the second quarter of 2026 was mainly affected by an unfavorable tax impact of a non-deductible acquired IPR&D charge related to the acquisition of Emalex and its primary asset ecopipam (EBS-101), the generation of profits in various jurisdictions in which tax rates are different than the Israeli tax rate and other infrequent or non-recurring items. (7) EPS difference and diluted non-GAAP EPS are calculated by dividing our non-GAAP net income attributable to Teva by our non-GAAP diluted weighted average number of shares. Reconciliation of gross profit to Non-GAAP gross profit (Unaudited) Three months ended Six months ended June 30, June 30, ($ in millions) 2026 2025 2026 2025 Gross profit $ 2,153 2,102 $ 4,124 3,979 Gross profit margin 52.0% 50.3% 50.8% 49.3% Increase (decrease) for excluded items: (1) Amortization of purchased intangible assets 129 138 257 273 Equity compensation 6 6 13 12 Other non-GAAP items 4 32 6 69 Non-GAAP gross profit $ 2,293 2,278 $ 4,401 4,332 Non-GAAP gross profit margin (2) 55.4% 54.6% 54.2% 53.7% (1) For further explanations, refer to the footnotes under the "Reconciliation of net income (loss) attributable to Teva to Non-GAAP net income (loss) attributable to Teva" table. (2) Non-GAAP gross profit margin is non-GAAP gross profit as a percentage of revenue. Reconciliation of operating income (loss) to Non-GAAP operating income (loss) (Unaudited) Three months ended Six months ended June 30, June 30, ($ in millions) 2026 2025 2026 2025 Operating income (loss) ($) (231) 455 ($) 421 975 Operating margin (5.6%) 10.9% 5.2% 12.1% Increase (decrease) for excluded items: (1) Amortization of purchased intangible assets 139 148 276 292 Legal settlements and loss contingencies 230 166 302 249 Impairment of long-lived assets 113 99 122 177 Restructuring costs 38 154 63 168 Equity compensation 40 38 83 72 Contingent consideration 17 19 22 30 Loss (gain) on sale of business 1 5 (4) 13 Other non-GAAP items 28 48 45 103 Non-GAAP operating income (loss) ($) 375 1,133 ($) 1,331 2,079 Non-GAAP operating margin (2) ($) 9.0% 27.1% ($) 16.4% 25.8% (1) For further explanations, refer to the footnotes under the "Reconciliation of net income (loss) attributable to Teva to Non-GAAP net income (loss) attributable to Teva" table. (2) Non-GAAP operating margin is Non-GAAP operating income as a percentage of revenues. Reconciliation of net income (loss) to adjusted EBITDA (Unaudited) Three months ended Six months ended June 30, June 30, ($ in millions) 2026 2025 2026 2025 Net income (loss) $ (575) 283 $ (206) 503 Increase (decrease) for excluded items: (1) Financial expenses 224 252 440 477 Income taxes 121 (78) 188 (4) Share in profits (losses) of associated companies –net § (1) 1 (1) Depreciation 102 103 205 201 Amortization 139 148 276 292 EBITDA 10 705 902 1,468 Legal settlements and loss contingencies 230 166 302 249 Impairment of long lived assets 113 99 122 177 Restructuring costs 38 154 63 168 Equity compensation 40 38 83 72 Contingent consideration 17 19 22 30 Loss (Gain) on sale of Business 1 5 (4) 13 Other non-GAAP items 25 45 39 97 Adjusted EBITDA $ 474 1,233 $ 1,529 2,274 (1) For further explanations, refer to the footnotes under the "Reconciliation of net income (loss) attributable to Teva to Non-GAAP net income (loss) attributable to Teva" table. § Represents an amount of less than $0.5 million. Segment Information (Unaudited) United States Europe International Markets Three months ended June30, Three months ended June 30, Three months ended June 30, 2026 2025 2026 2025 2026 2025 (U.S. $ in millions) (U.S. $ in millions) (U.S. $ in millions) Revenues $ 1,702 $ 1,786 $ 1,263 $ 1,298 $ 550 $ 495 Cost of sales 499 574 559 581 266 251 Gross profit 1,203 1,211 704 717 284 243 R&D expenses 883 152 52 59 26 24 S&M expenses 294 250 222 228 128 114 G&A expenses 107 111 66 66 38 32 Other (5) § (3) § (8) (1) Segment profit* $ (76) $ 699 $ 367 $ 364 $ 99 $ 74 * Segment profit does not include amortization and certain other items. § Represents an amount less than $0.5 million. Segment Information (Unaudited) United States Europe International Markets Six months ended June 30, Six months ended June 30, Six months ended June 30, 2026 2025 2026 2025 2026 2025 (U.S. $ in millions) (U.S. $ in millions) (U.S. $ in millions) Revenues $ 3,236 $ 3,322 $ 2,603 $ 2,492 $ 1,074 $ 1,077 Cost of sales 995 1,097 1,165 1,117 547 556 Gross profit 2,241 2,225 1,438 1,374 527 521 R&D expenses 1,030 306 97 120 49 49 S&M expenses 593 493 437 427 245 232 G&A expenses 197 206 139 135 77 72 Other (9) 3 (3) § (7) (2) Segment profit $ 431 $ 1,216 $ 768 $ 693 $ 164 $ 171 § Represents an amount less than $0.5 million. Reconciliation of our segment profit to consolidated income (loss) before income taxes (Unaudited) Three months ended June 30, 2026 2025 (U.S.$ in millions) United States profit $ (76) $ 699 Europe profit 367 364 International Markets profit 99 74 Total reportable segment profit 391 1,136 Profit (loss) of other activities (16) (3) Amounts not allocated to segments: Amortization 139 148 Other asset impairments, restructuring and other items 147 232 Intangible asset impairments 22 42 Legal settlements and loss contingencies 230 166 Other unallocated amounts 68 91 Consolidated operating income (loss) (231) 455 Financial expenses - net 224 252 Consolidated income (loss) before income taxes $ (455) $ 203 Reconciliation of our segment profit to consolidated income (loss) before income taxes (Unaudited) Six months ended June 30, 2026 2025 (U.S.$ in millions) United States profit $ 431 $ 1,216 Europe profit 768 693 International Markets profit 164 171 Total reportable segment profit 1,363 2,080 Profit (loss) of other activities (32) (1) Amounts not allocated to segments: Amortization 276 292 Other asset impairments, restructuring and other items 173 210 Intangible asset impairments 30 163 Legal settlements and loss contingencies 302 249 Other unallocated amounts 128 190 Consolidated operating income (loss) 421 975 Financial expenses - net 440 477 Consolidated income (loss) before income taxes $ (18) $ 497 Segment revenues by major products and activities (Unaudited) Three months ended Percentage June 30, Change 2026 2025 2026-2025 (U.S.$ in millions) United States segment Generic products (including biosimilars) $ 660 $ 961 (31%) AJOVY ® 116 63 83% AUSTEDO 676 495 37% BENDEKA ® and TREANDA ® 28 40 (30%) COPAXONE 61 62 (2%) UZEDY 77 54 43% Other* 84 111 (25%) Total 1,702 1,786 (5%) *Other revenues in the first quarter of 2026 include the sale of certain product rights. Three months ended Percentage June 30, Change 2026 2025 2026-2025 (U.S.$ in millions) Europe segment Generic products (including OTC and biosimilars) $ 1,024 $ 1,040 (2%) AJOVY 78 71 10% COPAXONE 49 50 (2%) Respiratory products 58 55 6% Other* 54 81 (34%) Total 1,263 1,298 (3%) *Other revenues in the first quarter of 2026 and 2025 include the sale of certain product rights. Three months ended Percentage June 30, Change 2026 2025 2026-2025 (U.S.$ in millions) International Markets segment Generic products (including OTC and biosimilars) $ 419 $ 410 2% AJOVY 49 20 146% AUSTEDO 20 3 571% COPAXONE 8 7 7% Other* 55 55 (1%) Total 550 495 11% *Other revenues in the first quarter of 2026 and 2025 include the sale of certain product rights. Segment revenues by major products and activities (Unaudited) Six months ended Percentage June 30, Change 2026 2025 2026-2025 (U.S.$ in millions) United States segment Generic products $ 1,272 $ 1,809 (30%) AJOVY 203 117 74% AUSTEDO 1,236 891 39% BENDEKA / TREANDA 55 76 (28%) COPAXONE 124 116 7% UZEDY 140 93 51% Other 206 220 (6%) Total 3,236 3,322 (3%) Six months ended Percentage June 30, Change 2026 2025 2026-2025 (U.S.$ in millions) Europe segment Generic products $ 2,113 $ 2,029 4% AJOVY 154 129 19% COPAXONE 89 92 (3%) Respiratory products 117 110 7% Other* 130 132 (1%) Total 2,603 2,492 4% *Other revenues in the first six months of 2026 and 2025 include the sale of certain product rights. Six months ended Percentage June 30, Change 2026 2025 2026-2025 (U.S.$ in millions) International Markets segment Generic products $ 805 $ 878 (8%) AJOVY 83 48 72% AUSTEDO 39 18 120% COPAXONE 13 17 (23%) Other* 134 116 15% Total 1,074 1,077 § *Other revenues in the first six months of 2026 and 2025 include the sale of certain product rights. § Represents an amount less than 0.5 Free cash flow reconciliation (Unaudited) Three months ended June 30, 2026 2025 (U.S. $ in millions) Net cash provided by (used in) operating activities 411 227 Beneficial interest collected in exchange for securitized accounts receivables 311 336 Capital investment (104) (96) Proceeds from divestitures of businesses and other assets, net 4 9 Free cash flow $ 622 $ 476 Free cash flow reconciliation (Unaudited) Six months ended June 30, 2026 2025 (U.S. $ in millions) Net cash provided by (used in) operating activities 371 122 Beneficial interest collected in exchange for securitized trade receivables 665 658 Capital investment (273) (223) Proceeds from divestitures of businesses and other assets, net 46 26 Free cash flow $ 810 $ 583 Net debt reconciliation unaudited June 30, 2026 Short-term debt 4,500 Senior notes and loans 12,092 Total debt 16,593 Net of cash and cash equivalents 3,655 Net debt $ 12,938 Teva Media Inquiries TevaCommunicationsNorthAmerica@tevapharm.com Teva Investor Relations Inquiries TevaIR@Tevapharm.com A PDF accompanying this announcement is available at

License out/inAcquisitionPhase 1NDAFinancial Statement

100 Deals associated with Fremanezumab-VFRM

External Link

KEGG	Wiki	ATC	Drug Bank
D11055	Fremanezumab-VFRM	N02CD03	DB14041

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Migraine Disorders	United States	Teva Pharmaceuticals USA, Inc.	14 Sep 2018

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Cluster Headache	Phase 3	United States	Teva Branded Pharmaceutical Products R&D LLC	17 Jan 2017
Cluster Headache	Phase 3	Australia	Teva Branded Pharmaceutical Products R&D LLC	17 Jan 2017
Cluster Headache	Phase 3	Canada	Teva Branded Pharmaceutical Products R&D LLC	17 Jan 2017
Cluster Headache	Phase 3	Finland	Teva Branded Pharmaceutical Products R&D LLC	17 Jan 2017
Cluster Headache	Phase 3	Germany	Teva Branded Pharmaceutical Products R&D LLC	17 Jan 2017
Cluster Headache	Phase 3	Israel	Teva Branded Pharmaceutical Products R&D LLC	17 Jan 2017
Cluster Headache	Phase 3	Italy	Teva Branded Pharmaceutical Products R&D LLC	17 Jan 2017
Cluster Headache	Phase 3	Netherlands	Teva Branded Pharmaceutical Products R&D LLC	17 Jan 2017
Cluster Headache	Phase 3	Poland	Teva Branded Pharmaceutical Products R&D LLC	17 Jan 2017
Cluster Headache	Phase 3	Spain	Teva Branded Pharmaceutical Products R&D LLC	17 Jan 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04530110 (CTgov)	Phase 3	Migraine Disorders	499	Fremanezumab (Fremanezumab 120 mg)	csbugmjjdm = yttpkhmhxi itegaatphv (cuezmxovhg, bloagimkns - yaeadwtykr) View more	-	24 Jul 2026
				Fremanezumab (Fremanezumab 225 mg)	csbugmjjdm = fnffgkvxuy itegaatphv (cuezmxovhg, myhxgkguux - gawimcbptm) View more
AAN2026	Not Applicable	Migraine Disorders	17,220	Erenumab	elbfaauhey(xgjocmlpir) = udbturuoun lpvbwzwbcq (bpmhamlipd, 0.96 - 1.21) View more	Positive	25 Apr 2026
				Fremanezumab	yvweuxycgk(ancdbvnygg) = kbtifdbmlm xjwegbjmyg (qidninoohl ) View more
PEARL (AAN2026)	Phase 4	Migraine Disorders	1,129	Fremanezumab	ueybdkvqfp(iqoizffyxt) = Among 295 participants with documented fremanezumab cessation and reinitiation, mean MMD decreased from 9.6 at baseline of reinitiation to 6.8 at Month 1 and 6.1 at Month 3 after reinitiation, both values remaining higher than before treatment discontinuation (5.9). ytlneooybm (zocozbibrs )	Positive	25 Apr 2026
				Fremanezumab (episodic migraine, 0-2 prior preventive treatment failures)
NCT04458857 (AAN2026)	Phase 3	Migraine Disorders	523	Fremanezumab	vqzkabvezs(dzvtbzsgbk) = ekiqbymsek mxyiujcqcb (gcaojxaywk ) View more	Positive	25 Apr 2026
				Placebo	vqzkabvezs(dzvtbzsgbk) = kkhapztbiv mxyiujcqcb (gcaojxaywk ) View more
NCT04464707 (CTgov)	Phase 3	Migraine Disorders	292	Placebo	ajfzzmtnda(jylgkwyiuh) = osfyhdloak fuzmvvcroc (phytewiput, 0.78) View more	-	19 Dec 2025
WCN2025	Not Applicable	Migraine Disorders	1,096	Fremanezumab	akhxvowisa(hnfoffnrre) = qdlkabcdol usnhpgpydv (vuoekuhlaw ) View more	Positive	12 Oct 2025
PEARL (EAN2025)	Phase 4	Migraine Disorders	1,129	Fremanezumab	vfjvkvvbqb(rgztxuksbu) = hkhxspjeoq qiouplciqk (tlbfpdkikd ) View more	Positive	21 Jun 2025
PEARL (EAN2025)	Phase 4	Migraine Disorders	1,140	Fremanezumab	fkvroxjvpc(tuabpgtcgi) = lfemingdrq cceevdwmbi (bpedktlfjt ) View more	Positive	21 Jun 2025
NCT04041284 (UNITE, Pubmed) Manual	Phase 4	Migraine Disorders \| Depressive Disorder, Major	540	fremanezumab	xahtvkvkrf(plmkrsyejg) = bmpawbpgjk nsipxbbxss (kconfinedo, -6.09 to -4.13) View more	Positive	05 May 2025
				Placebo	xahtvkvkrf(plmkrsyejg) = dauzppiuxp nsipxbbxss (kconfinedo, -3.89 to -1.96) View more
NCT04458857 (SPACE \| SPACE study, CTgov)	Phase 3	Migraine Disorders	235	Placebo (Placebo)	prifggbczw(evniyjyogt) = wcbigsriow pgtwhdckan (tnkincufak, 0.39) View more	-	16 Apr 2025
				Fremanezumab (Fremanezumab Dose A)	asyqyxstio = yirvwdskxs wodpjkcjig (gjojqqlctn, edtsakheeb - vvbdcchcua) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis